Table 2 Safety overview.
Safety overview | All patients (N = 47) N (%) |
|---|---|
Patients with TEAE | 46 (97.9) |
Patients with treatment-related AE | 32 (68.1) |
Patients with SAE | 17 (36.2) |
Patients with treatment-related SAE | 5 (10.6) |
Patients with Grade 3 or above AE | 23 (48.9) |
Patients with Grade 3 or above treatment related AE | 6 (12.8) |
Patients with AE leading to treatment discontinuation | 10 (21.3) |
Patients with treatment related AE leading to treatment discontinuation | 5 (10.6) |
Patients with AE leading to death | 4 (8.5) |
Patients with treatment related AE leading to death | 0 |
Patients with DLT | 1 (2.1) |
